> top > docs > PubMed:20470445 > annotations

PubMed:20470445 JSONTXT

Annnotations TAB JSON ListView MergeView

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-145 Sentence denotes Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
TextSentencer_T2 146-157 Sentence denotes BACKGROUND:
TextSentencer_T3 158-439 Sentence denotes The orally active quinoline-3-carboxamide tasquinimod [ABR-215050; CAS number 254964-60-8), which currently is in a phase II-clinical trial in patients against metastatic prostate cancer, exhibits anti-tumor activity via inhibition of tumor angiogenesis in human and rodent tumors.
TextSentencer_T4 440-605 Sentence denotes To further explore the mode of action of tasquinimod, in vitro and in vivo experiments with gene microarray analysis were performed using LNCaP prostate tumor cells.
TextSentencer_T5 606-760 Sentence denotes The array data were validated by real-time semiquantitative reversed transcriptase polymerase chain reaction (sqRT-PCR) and protein expression techniques.
TextSentencer_T6 761-769 Sentence denotes RESULTS:
TextSentencer_T7 770-914 Sentence denotes One of the most significant differentially expressed genes both in vitro and in vivo after exposure to tasquinimod, was thrombospondin-1 (TSP1).
TextSentencer_T8 915-1078 Sentence denotes The up-regulation of TSP1 mRNA in LNCaP tumor cells both in vitro and in vivo correlated with an increased expression and extra cellular secretion of TSP1 protein.
TextSentencer_T9 1079-1386 Sentence denotes When nude mice bearing CWR-22RH human prostate tumors were treated with oral tasquinimod, there was a profound growth inhibition, associated with an up-regulation of TSP1 and a down- regulation of HIF-1 alpha protein, androgen receptor protein (AR) and glucose transporter-1 protein within the tumor tissue.
TextSentencer_T10 1387-1609 Sentence denotes Changes in TSP1 expression were paralleled by an anti-angiogenic response, as documented by decreased or unchanged tumor tissue levels of VEGF (a HIF-1 alpha down stream target) in the tumors from tasquinimod treated mice.
TextSentencer_T11 1610-1622 Sentence denotes CONCLUSIONS:
TextSentencer_T12 1623-1895 Sentence denotes We conclude that tasquinimod-induced up-regulation of TSP1 is part of a mechanism involving down-regulation of HIF1alpha and VEGF, which in turn leads to reduced angiogenesis via inhibition of the "angiogenic switch", that could explain tasquinimods therapeutic potential.
T1 0-145 Sentence denotes Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
T2 146-157 Sentence denotes BACKGROUND:
T3 158-439 Sentence denotes The orally active quinoline-3-carboxamide tasquinimod [ABR-215050; CAS number 254964-60-8), which currently is in a phase II-clinical trial in patients against metastatic prostate cancer, exhibits anti-tumor activity via inhibition of tumor angiogenesis in human and rodent tumors.
T4 440-605 Sentence denotes To further explore the mode of action of tasquinimod, in vitro and in vivo experiments with gene microarray analysis were performed using LNCaP prostate tumor cells.
T5 606-760 Sentence denotes The array data were validated by real-time semiquantitative reversed transcriptase polymerase chain reaction (sqRT-PCR) and protein expression techniques.
T6 761-769 Sentence denotes RESULTS:
T7 770-914 Sentence denotes One of the most significant differentially expressed genes both in vitro and in vivo after exposure to tasquinimod, was thrombospondin-1 (TSP1).
T8 915-1078 Sentence denotes The up-regulation of TSP1 mRNA in LNCaP tumor cells both in vitro and in vivo correlated with an increased expression and extra cellular secretion of TSP1 protein.
T9 1079-1386 Sentence denotes When nude mice bearing CWR-22RH human prostate tumors were treated with oral tasquinimod, there was a profound growth inhibition, associated with an up-regulation of TSP1 and a down- regulation of HIF-1 alpha protein, androgen receptor protein (AR) and glucose transporter-1 protein within the tumor tissue.
T10 1387-1609 Sentence denotes Changes in TSP1 expression were paralleled by an anti-angiogenic response, as documented by decreased or unchanged tumor tissue levels of VEGF (a HIF-1 alpha down stream target) in the tumors from tasquinimod treated mice.
T11 1610-1622 Sentence denotes CONCLUSIONS:
T12 1623-1895 Sentence denotes We conclude that tasquinimod-induced up-regulation of TSP1 is part of a mechanism involving down-regulation of HIF1alpha and VEGF, which in turn leads to reduced angiogenesis via inhibition of the "angiogenic switch", that could explain tasquinimods therapeutic potential.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 13-16 gene:29 denotes ABR
T1 129-144 disease:C0033578 denotes prostate tumors
T2 103-119 gene:7057 denotes thrombospondin-1
T3 129-144 disease:C0033578 denotes prostate tumors
R1 T0 T1 associated_with ABR,prostate tumors
R2 T2 T3 associated_with thrombospondin-1,prostate tumors

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 329-344 HP_0012125 denotes prostate cancer
T2 338-344 HP_0002664 denotes cancer
T3 360-365 HP_0002664 denotes tumor
T4 393-398 HP_0002664 denotes tumor
T5 432-438 HP_0002664 denotes tumors
T6 584-598 HP_0012125 denotes prostate tumor
T7 593-598 HP_0002664 denotes tumor

Allie

Id Subject Object Predicate Lexical cue
SS1_20470445_4_0 649-714 expanded denotes semiquantitative reversed transcriptase polymerase chain reaction
SS2_20470445_4_0 716-724 abbr denotes sqRT-PCR
SS1_20470445_6_0 890-906 expanded denotes thrombospondin-1
SS2_20470445_6_0 908-912 abbr denotes TSP1
SS1_20470445_8_0 1297-1322 expanded denotes androgen receptor protein
SS2_20470445_8_0 1324-1326 abbr denotes AR
AE1_20470445_4_0 SS1_20470445_4_0 SS2_20470445_4_0 abbreviatedTo semiquantitative reversed transcriptase polymerase chain reaction,sqRT-PCR
AE1_20470445_6_0 SS1_20470445_6_0 SS2_20470445_6_0 abbreviatedTo thrombospondin-1,TSP1
AE1_20470445_8_0 SS1_20470445_8_0 SS2_20470445_8_0 abbreviatedTo androgen receptor protein,AR

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
20470445-0#13#16#gene29 13-16 gene29 denotes ABR
20470445-0#103#119#gene7057 103-119 gene7057 denotes thrombospondin-1
20470445-0#129#144#diseaseC0033578 129-144 diseaseC0033578 denotes prostate tumors
20470445-1#67#70#gene9564 225-228 gene9564 denotes CAS
20470445-1#67#70#gene1434 225-228 gene1434 denotes CAS
20470445-1#67#70#gene1500 225-228 gene1500 denotes CAS
20470445-1#67#70#gene9564 225-228 gene9564 denotes CAS
20470445-1#67#70#gene1434 225-228 gene1434 denotes CAS
20470445-1#67#70#gene1500 225-228 gene1500 denotes CAS
20470445-1#55#58#gene29 213-216 gene29 denotes ABR
20470445-1#160#186#diseaseC0936223 318-344 diseaseC0936223 denotes metastatic prostate cancer
20470445-1#160#186#diseaseC1282496 318-344 diseaseC1282496 denotes metastatic prostate cancer
20470445-1#160#186#diseaseC0936223 318-344 diseaseC0936223 denotes metastatic prostate cancer
20470445-1#160#186#diseaseC1282496 318-344 diseaseC1282496 denotes metastatic prostate cancer
20470445-1#160#186#diseaseC0936223 318-344 diseaseC0936223 denotes metastatic prostate cancer
20470445-1#160#186#diseaseC1282496 318-344 diseaseC1282496 denotes metastatic prostate cancer
20470445-1#235#253#diseaseC1519670 393-411 diseaseC1519670 denotes tumor angiogenesis
20470445-1#235#253#diseaseC1519670 393-411 diseaseC1519670 denotes tumor angiogenesis
20470445-6#197#208#gene3091 1276-1287 gene3091 denotes HIF-1 alpha
20470445-6#218#235#gene367 1297-1314 gene367 denotes androgen receptor
20470445-6#38#53#diseaseC0033578 1117-1132 diseaseC0033578 denotes prostate tumors
20470445-8#125#129#gene7422 1748-1752 gene7422 denotes VEGF
20470445-8#198#215#diseaseC1510885 1820-1837 diseaseC1510885 denotes "angiogenic switc
13#16#gene29129#144#diseaseC0033578 20470445-0#13#16#gene29 20470445-0#129#144#diseaseC0033578 associated_with ABR,prostate tumors
103#119#gene7057129#144#diseaseC0033578 20470445-0#103#119#gene7057 20470445-0#129#144#diseaseC0033578 associated_with thrombospondin-1,prostate tumors
67#70#gene9564160#186#diseaseC0936223 20470445-1#67#70#gene9564 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene9564160#186#diseaseC1282496 20470445-1#67#70#gene9564 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene9564160#186#diseaseC0936223 20470445-1#67#70#gene9564 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene9564160#186#diseaseC1282496 20470445-1#67#70#gene9564 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene9564160#186#diseaseC0936223 20470445-1#67#70#gene9564 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene9564160#186#diseaseC1282496 20470445-1#67#70#gene9564 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene9564235#253#diseaseC1519670 20470445-1#67#70#gene9564 20470445-1#235#253#diseaseC1519670 associated_with CAS,tumor angiogenesis
67#70#gene9564235#253#diseaseC1519670 20470445-1#67#70#gene9564 20470445-1#235#253#diseaseC1519670 associated_with CAS,tumor angiogenesis
67#70#gene1434160#186#diseaseC0936223 20470445-1#67#70#gene1434 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene1434160#186#diseaseC1282496 20470445-1#67#70#gene1434 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene1434160#186#diseaseC0936223 20470445-1#67#70#gene1434 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene1434160#186#diseaseC1282496 20470445-1#67#70#gene1434 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene1434160#186#diseaseC0936223 20470445-1#67#70#gene1434 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene1434160#186#diseaseC1282496 20470445-1#67#70#gene1434 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene1434235#253#diseaseC1519670 20470445-1#67#70#gene1434 20470445-1#235#253#diseaseC1519670 associated_with CAS,tumor angiogenesis
67#70#gene1434235#253#diseaseC1519670 20470445-1#67#70#gene1434 20470445-1#235#253#diseaseC1519670 associated_with CAS,tumor angiogenesis
67#70#gene1500160#186#diseaseC0936223 20470445-1#67#70#gene1500 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene1500160#186#diseaseC1282496 20470445-1#67#70#gene1500 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene1500160#186#diseaseC0936223 20470445-1#67#70#gene1500 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene1500160#186#diseaseC1282496 20470445-1#67#70#gene1500 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene1500160#186#diseaseC0936223 20470445-1#67#70#gene1500 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene1500160#186#diseaseC1282496 20470445-1#67#70#gene1500 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene1500235#253#diseaseC1519670 20470445-1#67#70#gene1500 20470445-1#235#253#diseaseC1519670 associated_with CAS,tumor angiogenesis
67#70#gene1500235#253#diseaseC1519670 20470445-1#67#70#gene1500 20470445-1#235#253#diseaseC1519670 associated_with CAS,tumor angiogenesis
67#70#gene9564160#186#diseaseC0936223 20470445-1#67#70#gene9564 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene9564160#186#diseaseC1282496 20470445-1#67#70#gene9564 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene9564160#186#diseaseC0936223 20470445-1#67#70#gene9564 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene9564160#186#diseaseC1282496 20470445-1#67#70#gene9564 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene9564160#186#diseaseC0936223 20470445-1#67#70#gene9564 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene9564160#186#diseaseC1282496 20470445-1#67#70#gene9564 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene9564235#253#diseaseC1519670 20470445-1#67#70#gene9564 20470445-1#235#253#diseaseC1519670 associated_with CAS,tumor angiogenesis
67#70#gene9564235#253#diseaseC1519670 20470445-1#67#70#gene9564 20470445-1#235#253#diseaseC1519670 associated_with CAS,tumor angiogenesis
67#70#gene1434160#186#diseaseC0936223 20470445-1#67#70#gene1434 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene1434160#186#diseaseC1282496 20470445-1#67#70#gene1434 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene1434160#186#diseaseC0936223 20470445-1#67#70#gene1434 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene1434160#186#diseaseC1282496 20470445-1#67#70#gene1434 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene1434160#186#diseaseC0936223 20470445-1#67#70#gene1434 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene1434160#186#diseaseC1282496 20470445-1#67#70#gene1434 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene1434235#253#diseaseC1519670 20470445-1#67#70#gene1434 20470445-1#235#253#diseaseC1519670 associated_with CAS,tumor angiogenesis
67#70#gene1434235#253#diseaseC1519670 20470445-1#67#70#gene1434 20470445-1#235#253#diseaseC1519670 associated_with CAS,tumor angiogenesis
67#70#gene1500160#186#diseaseC0936223 20470445-1#67#70#gene1500 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene1500160#186#diseaseC1282496 20470445-1#67#70#gene1500 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene1500160#186#diseaseC0936223 20470445-1#67#70#gene1500 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene1500160#186#diseaseC1282496 20470445-1#67#70#gene1500 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene1500160#186#diseaseC0936223 20470445-1#67#70#gene1500 20470445-1#160#186#diseaseC0936223 associated_with CAS,metastatic prostate cancer
67#70#gene1500160#186#diseaseC1282496 20470445-1#67#70#gene1500 20470445-1#160#186#diseaseC1282496 associated_with CAS,metastatic prostate cancer
67#70#gene1500235#253#diseaseC1519670 20470445-1#67#70#gene1500 20470445-1#235#253#diseaseC1519670 associated_with CAS,tumor angiogenesis
67#70#gene1500235#253#diseaseC1519670 20470445-1#67#70#gene1500 20470445-1#235#253#diseaseC1519670 associated_with CAS,tumor angiogenesis
55#58#gene29160#186#diseaseC0936223 20470445-1#55#58#gene29 20470445-1#160#186#diseaseC0936223 associated_with ABR,metastatic prostate cancer
55#58#gene29160#186#diseaseC1282496 20470445-1#55#58#gene29 20470445-1#160#186#diseaseC1282496 associated_with ABR,metastatic prostate cancer
55#58#gene29160#186#diseaseC0936223 20470445-1#55#58#gene29 20470445-1#160#186#diseaseC0936223 associated_with ABR,metastatic prostate cancer
55#58#gene29160#186#diseaseC1282496 20470445-1#55#58#gene29 20470445-1#160#186#diseaseC1282496 associated_with ABR,metastatic prostate cancer
55#58#gene29160#186#diseaseC0936223 20470445-1#55#58#gene29 20470445-1#160#186#diseaseC0936223 associated_with ABR,metastatic prostate cancer
55#58#gene29160#186#diseaseC1282496 20470445-1#55#58#gene29 20470445-1#160#186#diseaseC1282496 associated_with ABR,metastatic prostate cancer
55#58#gene29235#253#diseaseC1519670 20470445-1#55#58#gene29 20470445-1#235#253#diseaseC1519670 associated_with ABR,tumor angiogenesis
55#58#gene29235#253#diseaseC1519670 20470445-1#55#58#gene29 20470445-1#235#253#diseaseC1519670 associated_with ABR,tumor angiogenesis
197#208#gene309138#53#diseaseC0033578 20470445-6#197#208#gene3091 20470445-6#38#53#diseaseC0033578 associated_with HIF-1 alpha,prostate tumors
218#235#gene36738#53#diseaseC0033578 20470445-6#218#235#gene367 20470445-6#38#53#diseaseC0033578 associated_with androgen receptor,prostate tumors
125#129#gene7422198#215#diseaseC1510885 20470445-8#125#129#gene7422 20470445-8#198#215#diseaseC1510885 associated_with VEGF,"""angiogenic switc"

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T1431 225-228 gene:9564 denotes CAS
T1432 318-344 disease:C0936223 denotes metastatic prostate cancer
T1433 393-411 disease:C1519670 denotes tumor angiogenesis
R1 T1431 T1432 associated_with CAS,metastatic prostate cancer
R2 T1431 T1432 associated_with CAS,metastatic prostate cancer
R3 T1431 T1432 associated_with CAS,metastatic prostate cancer
R4 T1431 T1432 associated_with CAS,metastatic prostate cancer
R5 T1431 T1432 associated_with CAS,metastatic prostate cancer
R6 T1431 T1432 associated_with CAS,metastatic prostate cancer
R7 T1431 T1433 associated_with CAS,tumor angiogenesis
R8 T1431 T1433 associated_with CAS,tumor angiogenesis
R9 T1431 T1433 associated_with CAS,tumor angiogenesis

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 1379-1385 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue
PD-UBERON-AE-B_T2 1508-1514 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 1379-1385 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue
PD-UBERON-AE-B_T2 1508-1514 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue